---
title: Five-year follow-up of a phase I trial of donor-derived modified immune cell
  infusion in kidney transplantation
date: '2023-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37483623/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230724180956&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: MIC infusions together with reduced conventional immunosuppression
  were associated with good graft function during five years of follow-up, no de novo
  DSA development and no opportunistic infections. In the future, MIC infusions might
  contribute to graft protection while reducing the side effects of immunosuppressive
  therapy. However, this approach needs further validation in direct comparison with
  prospective ...'
disable_comments: true
---
CONCLUSIONS: MIC infusions together with reduced conventional immunosuppression were associated with good graft function during five years of follow-up, no de novo DSA development and no opportunistic infections. In the future, MIC infusions might contribute to graft protection while reducing the side effects of immunosuppressive therapy. However, this approach needs further validation in direct comparison with prospective ...